Your Participation is Key

WELCOME TO NEW PARTICIPANTS

This web site is dedicated to the participants in CanCOLD
cohort, who give the world the gift of knowledge. By their
volunteer efforts, our understandings of the many interrelated factors that cause and prevent are and will continue to be discovered. In so doing, they help to improve and save lives.

HERE'S WHAT THEY HAD TO SAY
ABOUT CANCOLD...

“CanCOLD is the first study to characterize the Canadian population with respect to COPD, its
consequences on patients and our society. This study has unique feature ... and we fully support this important national research initiative”

Dr Yves Berthiaume, Director, Respiratory Health Network of the FRSQ.

“This proposal is an excellent example of the innovative, intuitive and cost-effective research ideas which exist in the Canadian Respiratory Community. This study aims to provide clarity around the existence of COPD in Canada by further developing an existing cohort to provide important insights into the natural progression of the disease, as well as the degree of disability and health status of Canadians whose lives are affected by it. In addition it promises to provide new information into changing demographics of COPD, a disease which is increasingly affecting more women and younger Canadians.”

Dr Tjark Reblin, VP Medical Division, GlaxoSmithKline Canada

“The CanCOLD Study will unite investigators from distinct yet complementary areas to further advance knowledge in COPD. From an industry perspective, the CanCOLD Study provides an important opportunity to consolidate resources and link together key Canadian researchers to address challenging and important research questions in a more focused and unified manner that could not be achieved otherwise.”

Dr Tomasz Uscinowisz, VP Medical, Boehringer Ingelheim (Canada) and Dr Lorella Garofalo, Director Medical Affairs, Pfizer Global Pharmaceuticals

“There is an urgent need to track the prevalence of COPD, to examine the influences of mild disease and sex, its manifestations and impacts on the patients and the health care system.”

Karen Felmate, AstraZeneca

YOUR THOUGHTS ARE IMPORTANT FOR US

A CanCOLD discussion forum is just about to be created. Periodically visit us to stay informed and join the CanCOLD forum.